The House is set to vote this week on a bill that seeks to limit monthly insulin costs for diabetics with private health plans and Medicare. House Bill 6833 would cap cost-sharing under private health plans and Medicare for a month’s supply of selected insulin products at $35 or 25% of a plan’s negotiated price, whichever is less. If the bill passes Congress, the cap would begin in 2023. Although the issue has bipartisan support, it is unclear whether this particular bill will pass the House.